Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase IIIb Study to Evaluate Efficacy and Safety of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)

NCT01808313 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01808313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01808313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase IIIb Study to Evaluate Efficacy and Safety of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
December 1, 2012
Completion date
August 15, 2014
Enrollment
134 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

vascular disease